Clearside Biomed Stock Price, News & Analysis

Clearside Biomedical (Nasdaq: CLSD) announced plans to explore strategic alternatives to advance its proprietary Suprachoroidal Space (SCS®) delivery platform and ophthalmology pipeline. The company has retained Piper Sandler to evaluate options including potential sale, licensing, partnerships, or other strategic transactions.

The company's key assets include their SCS Microinjector®, a proven in-office delivery platform for retinal therapies, and CLS-AX, their Phase 3-ready wet AMD treatment that achieved positive Phase 2b results. Due to challenging market conditions, Clearside will transition all employees to consulting roles and pause internal R&D programs during the strategic review.

Clearside has established five commercial and late-stage development licensing collaborations with partners including Aura Biosciences, Bausch + Lomb, BioCryst, REGENXBIO/AbbVie, and Arctic Vision/Santen.

Clearside Biomedical (NASDAQ: CLSD) announced multiple upcoming presentations featuring its SCS Microinjector platform at the Clinical Trials at the Summit Meeting on June 21, 2025, in Las Vegas. The presentations will showcase the platform's versatility in delivering various eye therapies through the suprachoroidal space. Key presentations include updates on CLS-AX for nAMD Phase 3 program, suprachoroidal ABBV-RGX-314 for DR treatment, and Bel-sar for choroidal melanoma Phase 3 trial. Dr. Victor Chong, CMO and EVP, emphasized the platform's capability as an in-office solution for vision-preserving therapies, highlighting its benefits of extended durability and flexible dosing for retinal diseases.

Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), will participate in the Stifel 2025 Virtual Ophthalmology Forum. The company's management will engage in a fireside chat on Tuesday, May 27, 2025, at 9:00 a.m. ET. Investors and interested parties can access the live and archived webcast through the Events and Presentations section of Clearside's website. The webcast recording will remain available for three months after the event.

Clearside Biomedical (NASDAQ: CLSD) reported Q1 2025 financial results and corporate updates. Key highlights include a successful End-of-Phase 2 FDA meeting for CLS-AX in wet AMD, targeting a flexible three-to-six-month dosing label. Q1 revenue was $2.3 million, up from $0.2M in Q1 2024, driven by partner milestone payments. Net loss decreased to $8.2 million ($0.11/share) from $11.8M ($0.17/share) year-over-year. The company's cash position stands at $13.6 million, expected to fund operations into Q4 2025. Notable partner progress includes ARCATUS® approvals in Australia and Singapore, and an NDA under review in China. BioCryst Pharmaceuticals received authorization to start clinical trials for avoralstat in Australia using Clearside's SCS Microinjector®.

Clearside Biomedical (NASDAQ: CLSD) showcased six presentations at the ARVO 2025 Meeting, highlighting their CLS-AX (axitinib injectable suspension) program and suprachoroidal drug delivery platform. The Phase 2b ODYSSEY trial for CLS-AX demonstrated positive results in treating wet AMD, maintaining stable vision while reducing injection frequency. Key developments include:

• Development of the first machine learning algorithm for imaging suprachoroidal space (SCS) drug delivery
• Creation of a novel force analysis method for drug-device optimization
• Over 15,000 completed injections in their clinically validated training program
• Successful Phase 2b results supporting CLS-AX as a potential safe and long-acting therapy

The company's SCS Microinjector® technology positions Clearside as a leader in suprachoroidal drug delivery, offering a transformative approach to treating retinal diseases.

Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has scheduled the release of its first quarter 2025 financial results for Wednesday, May 14, 2025, after market close. The company has noted that it will not hold a conference call this quarter. Investors can access quarterly results and other investor-related information through the Investors section of Clearside's website.

Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), will participate in the Citizens Life Sciences Conference. The company's management will engage in a fireside chat on May 7, 2025, at 1:00 p.m. ET. Investors can access the live and archived webcast through Clearside's website under the Investors section: Events and Presentations. The webcast recording will remain available for three months after the event.

Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's leadership, including George Lasezkay, President and CEO, and Victor Chong, Chief Medical Officer and EVP of Research & Development, will engage in a fireside chat on Monday, April 7, 2025, at 12:45 p.m. ET. The presentation will be accessible via webcast through Clearside's website under the Investors section, with the recording remaining available for three months.

Clearside Biomedical (NASDAQ: CLSD) has announced its Q4 and full-year 2024 financial results. The company achieved a successful End-of-Phase 2 meeting with FDA for CLS-AX in wet AMD, aligning on Phase 3 plans. Their Asia-Pacific partner received regulatory acceptance for ARCATUS® in China for uveitic macular edema treatment.

Financial highlights for Q4 2024: Revenue was $0.3 million (down from $6.3M in Q4 2023), net loss increased to $7.3 million ($0.10 per share). Full-year 2024 results showed revenue of $1.7 million (down from $8.2M in 2023) and net loss of $34.4 million ($0.47 per share). Cash position stands at $20.0 million, sufficient to fund operations into Q4 2025.

The company's partners are advancing various clinical programs: REGENXBIO/AbbVie planning Phase 3 for sura-vec, Aura Biosciences enrolling for Phase 3 CoMpass trial, and BioCryst preparing to initiate clinical testing of avoralstat in 2025.